{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-25-000028","form_type":"8-K","ticker":"OTLC","cik":"0000908259","company_name":"Oncotelic Therapeutics, Inc.","filed_at":"2025-01-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:06.754377+00:00","generated_at":"2026-05-28T19:19:56.033410+00:00","sec_items":["8.01","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Oncotelic extends reverse merger deadline with Mosaic ImmunoEngineering to June 30, 2025","bullets":["Term sheet dated April 26, 2024, originally 90-day term, extended to Dec 31, 2024; now extended to June 30, 2025.","No definitive agreement reached; extension allows continued due diligence and documentation.","Both companies mutually agreed extension is in best interests; transaction remains conditional and not guaranteed.","Extension letter executed December 31, 2024; no other term sheet modifications."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-25-000028","json":"https://secwatch.observer/filing/0001493152-25-000028.json","markdown":"https://secwatch.observer/filing/0001493152-25-000028.md","text":"https://secwatch.observer/filing/0001493152-25-000028.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/908259/000149315225000028/0001493152-25-000028-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/908259/000149315225000028/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T19:19:56.033410+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}